Zeta SATB2 Antibody. Zeta’s recombinant rabbit antibody recognizes SATB2, a DNA binding protein specifically binds nuclear matrix attachment regions. SATB2 are part of the matrix attachment region binding transcription factor family, which consists of transcription factors binding to adenine and thymine (AT) rich regions in the nuclear matrix, capable of altering the chromatin structure. SATB2 is involved in transcription regulation and chromatin remodeling. SATB2 was first identified in 2002 and characterized as a gene involved in cleft palate defects.
SATB2 expression in colorectal carcinomas (CRC) is correlated with a good prognosis. In laryngeal squamous cell carcinoma, SATB2 functions as a tumor suppressor, wherein loss of expression is positively correlated with high tumor grade and recurrence. Moreover, SATB2, in combination with CK20, could identify almost all CRC’s. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origins are rarely positive SATB2. Additionally, SATB2 antibody can identify neuroendocrine neoplasms of the colon and rectum because SATB2 is usually negative in neuroendocrine neoplasms of the GI tract, pancreas, and lung. More recently, SAT2B has been reported that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.